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ABSTRACT
We investigated the selectivity of protopanaxadiol ginsenosides
from Panax ginseng acting as positive allosteric modulators on
P2X receptors. ATP-induced responses weremeasured in stable
cell lines overexpressing human P2X4 using a YOPRO-1 dye
uptake assay, intracellular calcium measurements, and whole-
cell patch-clamp recordings. Ginsenosides CK and Rd were
demonstrated to enhance ATP responses at P2X4 by ∼twofold,
similar to potentiation by the known positive modulator ivermec-
tin. Investigations into the role of P2X4 in mediating a cytotoxic
effect showed that only P2X7 expression in HEK-293 cells
induces cell death in response to high concentrations of ATP,
and that ginsenosides can enhance this process. Generation of a
P2X7-deficient clone of BV-2 microglial cells using CRISPR/
Cas9 gene editing enabled an investigation of endogenous P2X4
in amicroglial cell line. Comparedwith parental BV-2 cells, P2X7-
deficient BV-2 cells showed minor potentiation of ATP re-
sponses by ginsenosides, and insensitivity to ATP2 or ATP1
ginsenoside-induced cell death, indicating a primary role for
P2X7 receptors in both of these effects. Computational docking
to a homologymodel of human P2X4, based on the open state of
zfP2X4, yielded evidence of a putative ginsenoside binding site
in P2X4 in the central vestibule region of the large ectodomain.
Introduction
P2X receptors are a family of ATP-gated nonselective
cation channels of which there are seven known subunits
(P2X1–7) with varying expression patterns (North, 2002).
Their physiological roles range from the regulation of mem-
brane potential and intracellular calcium concentration (all
P2X receptors) to the regulation of mediator secretion such as
interleukin 1b (IL-1b) and brain-derived neurotrophic factor
(BDNF) by P2X7 and P2X4, respectively. Investigations into
drugs that can modulate the activity of P2X receptors have
been quite intensive in the last decade, with successful
identification of selective antagonists for many of the P2X
family, as reviewed in Bartlett et al. (2014) and Stokes et al.
(2017). We recently reported the identification of a series of
positive allosteric modulators of P2X7 found in extracts of
the traditional Chinese medicinal plant, Panax ginseng
(Helliwell et al., 2015). In this work, we have further inves-
tigated the selectivity of ginsenosides for P2X7 within the
P2X family, focusing on purinergic receptors typically coex-
pressed with P2X7 in immune cells, namely P2X4, P2Y1, and
P2Y2 (Bowler et al., 2003).
P2X4 is one of the most ubiquitously expressed P2X
receptors (Soto et al., 1996) and has been implicated in several
physiological pathways in different tissues. Prominent ex-
pression of P2X4 has been demonstrated in endothelial cells,
immune cells, and neurons, as reviewed in Stokes et al. (2017).
An important role for P2X4 in vasodilation responses to shear
stress was elucidated in 2000 (Yamamoto et al., 2000), and
transgenic mice lacking P2X4 later confirmed a role in nitric
oxide production and vessel remodelling (Yamamoto et al.,
2006). In the central nervous system (CNS), P2X4 has been
implicated in long-term potentiation (Sim et al., 2006) and in
the pathophysiology associated with neuropathic pain (Tsuda
et al., 2003; Coull et al., 2005). P2X4 expressed on spinal cord
microglia is involved in activation of microglia and release of
mediators, including BDNF, which alter sensory neuronal pain
transmission pathways (Coull et al., 2005;Ulmann et al., 2008).
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Also in the CNS, a role for P2X4 has been described in
alcohol-intake behavior due to regulation of the dopamine
reward pathway in the brain (Asatryan et al., 2011; Franklin
et al., 2015; Khoja et al., 2016). Finally, in the immune
system, P2X4 plays a role in the regulation of CXCL5
production and secretion from monocytes and macrophages
(Layhadi et al., 2018).
Many of the roles for P2X4 have been elucidated using
transgenic P2X42/2 mice or short hairpin RNA knockdown of
the receptor because selective and potent antagonists for
P2X4 have only recently been described. These include
PSB-12062, BX430, NP-1815-PX, and 5-(3-Bromophenyl)-
1,3-dihydro-2H-benzofuro[3,2-e]-1,4-diazepin-2-one (5-BDBD)
(Hernandez-Olmos et al., 2012; Balázs et al., 2013; Ase et al.,
2015;Matsumura et al., 2016; Stokes et al., 2017). In contrast
to antagonists, relatively few positive allosteric modulators
(PAMs) have been described for P2X receptors. Possibly the
best known PAM for P2X receptors is ivermectin, which has
most activity at P2X4 (Khakh et al., 1999b; Priel and Silberberg,
2004), although it also has some reported positive modulator
activity on human P2X7 (Nörenberg et al., 2012). Other than
ivermectin, cibacron blue, tenidap, clemastine, progesterone,
and tetrahydrodeoxycorticosterone have been identified as
positive modulators for P2X4, P2X7, and P2X2, respectively
(Miller et al., 1998; Sanz et al., 1998; De Roo et al., 2010;
Nörenberg et al., 2011). In addition, trace metals such as
zinc and copper have PAM activity at several P2X recep-
tors, including P2X2 and P2X4, as reviewed by Coddou
et al. (2011a,b).
Ginsenosides are triterpenoid saponins found in the root
extract of plants belonging to P. ginseng. Two subclasses of
ginsenosides exist, designated protopanaxadiols (PPD) and
protopanaxtriols (PPT) due to the positioning of glycoside
attachments on the molecules. Ginsenosides have been re-
ported to act on a number of ion channels such as voltage-
gated Na1 and K1 channels, GABAA, and 5-HT3 receptors
(Nah, 2014). Other constituents of ginseng such as the
glycolipoprotein gintonin have been shown to potentiate
P2X1 receptors (Choi et al., 2013). In our previous study
(Helliwell et al., 2015), we demonstrated that the major
ginsenoside metabolite generated in vivo, compound K (CK),
in addition to protopanaxadiol ginsenosides Rd, Rb1, and Rh2,
acts on P2X7 to potentiate the action of ATP. Ginsenosides
reduced the EC50 for the physiologic agonist, ATP, at mouse
and human P2X7 and enhanced ATP-induced cell death in the
J774 mouse macrophage cell line (Helliwell et al., 2015). In
this study, we demonstrate that the protopanaxadiol ginseno-
sides Rd and CK have a similar potentiating action on P2X4,
most likely through a highly similar binding site identified in
the central vestibule region; however, the magnitude of the
potentiating effect on P2X4 is less than at P2X7.
Materials and Methods
Materials. ATP (A7699; Sigma-Aldrich, St. Louis, MO) was pre-
pared in distilled water and adjusted to pH 7.4 with 5 M NaOH.
Aliquotswere stored at220°C and used only once. 5-(3-Bromophenyl)-
1,3-dihydro-2H-benzofuro[3,2-e]-1,4-diazepin-2-one (5-BDBD) (Tocris
Biosciences, Bio-Techne Ltd., Abingdon, U.K.) was prepared in
dimethylsulfoxide (DMSO) at 10 mM and stored at 220°C. PSB-
12062 (SML0753; Sigma-Aldrich) was prepared in distilled water to
10 mM. Ivermectin (Tocris Biosciences) was prepared at 30 mM in
DMSO and stored at 220°C. Ginsenosides CK, Rd, Rb1, Rh2, and
protopanaxadiol (PPD) (99% purity) were purchased from Shanghai
Richem International Ltd., Shanghai, China, and 10 mM stocks were
prepared in sterile DMSO (Sigma-Aldrich) in glass vials. Stock
solutions were stored at 220°C. The G115 standardized ginseng
extract was a gift of Professor C. C. Xue (RMIT University, Australia)
and was prepared in water, as described in Helliwell et al. (2015).
Cell Culture. Stably transfected HEK-293 cells were maintained
in Dulbecco’s modified Eagle’s medium (DMEM):F12 media contain-
ing L-glutamine (cat. no. 11320-034; Life Technologies, Fisher Scien-
tific, Waltham, MA) supplemented with 10% fetal bovine serum
(US origin, cat. no. F2442; Sigma-Aldrich) and 100 U/ml penicillin
plus 100 mg/ml streptomycin (Fisher Scientific, Waltham, MA). Stably
transfected 1321N1 cells were maintained in DMEM high-glucose
media supplemented with 10% fetal bovine serum and 100 U/ml
penicillin plus 100 mg/ml streptomycin. To maintain stable expression
of P2X constructs, 400–800 mg/ml geneticin (Gibco, Fisher Scientific)
was added to the culture media. Initial transient transfections of
HEK-293 cells were performed in 35-mm petri dishes using 0.1–1 mg
plasmid DNA (Glu-Glu-tagged hP2X4 or hP2X7 in pcDNA3) and
Lipofectamine 2000 (3 ml/mg DNA) complexes in OptiMem media
(Fisher Scientific). Cells were plated into 96-well plates (cat. no.
167008;Nunc, Fisher Scientific,Waltham,MA) precoatedwith 50mg/ml
poly-D-lysine (Merck Millipore, Burlington, MA), and plates were
incubated overnight before experiments.
Mouse microglial cell line BV-2 (a gift of Dr. B. Gu, Florey Institute
of Neurosciences, Melbourne) was maintained in DMEM:F12 media
containing L-glutamine (cat. no. 11320-034; Life Technologies) sup-
plemented with 10% fetal bovine serum (Sigma-Aldrich US origin,
F2442) and 100 U/ml penicillin plus 100 mg/ml streptomycin (Life
Technologies).
CRISPR/Cas9 Gene Editing. Complementary RNA was designed
against exon 2 of mouse P2RX7, and two RNA constructs were
purchased from Dharmacon (GE Healthcare, Chicago, IL). BV-2 cells
(120,000 cells/well) in a six-well plate were transfected with endotoxin-
free 1 mg EditR-Cas9 plasmid with blasticidin resistance (GE Health-
care Dharmacon, Lafayette, CO) plus 25 nM target RNA and 25 nM
complementary RNA for P2RX7 using Dharmafect DUO reagent (4 ml).
Following 24-hour incubation, media were replaced, and, after an
additional 72-hour incubation, blasticidin was added to a final concen-
tration of 1 mg/ml. Antibiotic selection was performed for 5 days, and
remaining cells were left to expand for analysis of gene editing. Cells
were tested for lack of P2X7 expression using flow cytometry. Successful
wells showing lack of P2X7 expression underwent single-cell cloning in
96-well plates, andmultiple clones were screened for lack of expression.
Genomic DNA was extracted from successful clones and amplified by
polymerase chain reaction for the P2RX7 exon 2 region. Polymerase
chain reaction products were sent for sequencing to verify mutations in
this region (Eurofins Genomics, Ebersberg, Germany).
Flow Cytometry and Immunofluorescence. BV-2 cells (5  105
cells) were stained with rat anti-mouse P2X7 antibody (Hano43; Enzo
Life Sciences UK Ltd, Exeter, U.K.) at 1:10 dilution in cold phosphate-
buffered saline (PBS)/0.5% bovine serum albumin (BSA) buffer. Stain-
ing was performed on ice for 1 hour. Cells were washed with PBS/0.5%
BSA buffer and stained with a goat anti-rat IgG Alexa488 secondary
antibody (Fisher Scientific) at 1:200 dilution for 1 hour on ice. Following
washing with PBS/0.5% BSA buffer, cells were resuspended in 300 ml
PBS/0.5%BSA buffer for acquisition on a FACSCalibur or on a Cytoflex
flow cytometer.
For immunofluorescence, cells were grown overnight on 13-mm
glass coverslips and washed with PBS prior to fixation with 4%
paraformaldehyde (Sigma-Aldrich). Cells were permeabilized using
PBS/0.5% BSA buffer containing 0.1% saponin (Sigma-Aldrich) and
blocked for 1 hour. Rabbit anti-P2X4 (Alomone Laboratories, Jerusalem,
Israel) was used at 1:200 dilution in PBS/0.5% BSA buffer, and cells
were stained overnight. Following washing, anti-rabbit IgG Alexa
568 was used at 1:200 dilution in PBS/0.5% BSA buffer. Coverslips
weremounted onto glass slides using ProlongGold antifade containing
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49,69-diamidino-2-phenylindole (Fisher Scientific). A Zeiss AxioPlan
2ie upright fluorescent microscope was used to take the images.
Western Blotting. Whole-cell lysates were prepared in radio-
immunoprecipitation assay lysis buffer (Fisher Scientific) containing
protease inhibitors (Fisher Scientific). Cell pellets were disrupted
with a pipette tip and lysed on ice for 30 minutes. Lysates were then
cleared by centrifugation at 10,000g for 10 minutes, and superna-
tants were transferred into clean tubes. Protein was measured
using a bicinchoninic acid assay (Pierce, Fisher Scientific, Waltham,
MA) with BSA as standard (2 mg/ml to 20 ng/ml). Absorbance at
562 nmwas measured using a Flexstation 3 plate reader (Molecular
Devices, San Jose, CA). A quantity amounting to 25 mg total protein
was loaded per lane onto a Bolt 4%–12% Bis–Tris gel (Fisher
Scientific) using the supplied gel-loading buffer plus reducing
agent. Electrophoresis was performed using 1MES buffer. Protein
was transferred onto polyvinylidene difluoride membrane (Immo-
bilon P; Fisher Scientific) using semidry transfer for 60 minutes.
Membranes were blocked with 5% nonfat milk solution in Tris-
buffered saline/Tween 20 (TBST) overnight at 4°C. Primary anti-
bodies were incubated for 2 hours at room temperature in 5% nonfat
milk solution in TBST. Anti-P2X4 (APR-004; Alomone Laborato-
ries) and anti-P2X7 C-terminal antibody (APR-002; Alomone Lab-
oratories) were both used at 1:2000 dilution. A goat anti-rabbit
IgG-horseradish peroxidase secondary (Sigma-Aldrich) was used at
1:2000 dilution. Blots were stripped, washed, reblocked, and then
reprobed for b-actin using a mouse monoclonal anti–b-actin anti-
body (A5316; Sigma-Aldrich) at 1:2000 dilution in 5% nonfat milk
solution in TBST. An anti-mouse IgG-horseradish peroxidase
(Sigma-Aldrich) secondary was used at 1:10,000 dilution. Luminata
chemiluminescent substrate (Merck Millipore) was used to de-
velop blots, and images were taken using an Image Quant LAS
4000 imager.
Dye Uptake Experiments. For YOPRO-1 dye uptake experi-
ments, cells were plated at a density of 2  104 cells/well in complete
DMEM:F12 media (100 ml per well) in poly-D-lysine–coated 96-well
plates. Media were removed using amanualmultichannel pipette and
replaced with a low divalent cation buffer (145 mM NaCl, 2 mM KCl,
13 mM D-glucose, 10 mM HEPES, and 0.1 mM CaCl2, pH 7.3)
containing 2 mMYO-PRO-1 iodide (cat. no. Y3663; Life Technologies).
For preincubation experiments, the cells were treated with ginseno-
sides (10 mM) in YO-PRO–containing low divalent cation buffer. For
the majority of experiments, ginsenosides were coinjected simulta-
neously with the agonist using a Flexstation 3 microplate reader
(Molecular Devices). Ginsenosides and agonist were prepared at 10
final concentration in the compound plate. Dye uptake over time was
recorded using an excitation wavelength of 488 nm and an emission
wavelength of 520 nm on the Flexstation 3 (six reads/well, photo-
multiplier tube (PMT) setting medium). Basal fluorescence measure-
ments were acquired for 40 seconds, followed by automatic injection of
agonist, and the kinetic measurement of fluorescence intensity was
performed for 300 seconds using Softmax Pro v5.4 software. Dye
uptake responses were calculated as area under the curve from 50 to
300 seconds using zero baseline normalized data.
Intracellular Calcium Measurements. HEK-293, HEK-hP2X4
cells, and 1321N1-hP2X4 cells in poly-D-lysine–coated 96-well plates
were loaded with 2 mM Fura-2 acetoxymethyl ester (Fisher Scientific
or HelloBio, Bristol, U.K.) in Hanks’ balanced salt solution buffer
containing 250 mM sulfinpyrazone (Sigma-Aldrich) for 40–60 minutes
Fig. 1. Protopanaxadiol ginsenosides and G115 increase hP2X4-mediated YOPRO-1 uptake responses. (A) Representative data showing YOPRO-1
uptake in response to ATP (5 mM) in the presence of ivermectin (IVM, 3 mM) or 5-BDBD (20 mM). (B) Summary area under curve data from normalized
YOPRO-1 uptake in HEK-hP2X4 cells (n = 3 independent experiments). Error bars represent S.D.; *represents P , 0.05 by one-way ANOVA with
Dunnett’s multiple comparison post hoc test. (C) YOPRO-1 uptake responses in HEK-hP2X4 cells to ATP (5 mM) in low divalent buffer solution (black) or
ATP plus PPD (purple; 10 mM) and ATP plus CK (red; 10 mM). Ginsenosides were coinjected with the agonist ATP. (D) Data have been quantified as
area under dye uptake curve (50–180 seconds). Bar graphs show data from three to five independent experiments. Error bars represent S.D.; *represents
P , 0.05 by one-way ANOVA with Dunnett’s multiple comparison post hoc test, ns represents not significant.
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at 37°C. Following loading, buffer was removed using a multichannel
pipette and replacedwith standard extracellular buffer or lowdivalent
buffer. Cells were warmed for 10 minutes before measurements were
started. Fura-2 was measured at excitation wavelengths 340 and
380 nm with emission wavelength 520 nm using a Flexstation 3 plate
reader. Sampling interval was 3.5 seconds and three reads/well. Fura-2
ratio was calculated using Softmax Pro v5.4, and responses were
measured using area under curve kinetic reduction.
Calcium responses in parental and P2X7-deficient BV-2 cells were
performed using a Fura-2-QBT kit (Molecular Devices). Reagent was
prepared in low divalent buffer containing 250mMsulfinpyrazone and
added to cells plated into poly-D-lysine–coated 96-well plates for
60 minutes (180 ml/well). Using the Fura-2-QBT kit eliminated the
washing step from the procedure, ensuring that no cells were lost from
the plate. Fura-2 fluorescence was measured at excitation wave-
lengths 340 and 380 nm with emission wavelength 520 nm using a
Flexstation 3 plate reader. Sampling interval was 3.5 seconds and
three reads/well. Fura-2 ratio was calculated using Softmax Pro v5.4,
and responses were measured using area under curve kinetic re-
duction. Conditions were applied in triplicate, and experiments were
performed four independent times.
Cell Viability. Viability experiments were performed using the
CellTiter 96 Aqueous Non-Radioactive Cell Proliferation assay (G3580,
Promega, Madison, WI), a colorimetric method for determining the
number of viable cells. HEK-293 cells were plated at 5  104 cells/well
in complete DMEM:F12 media and left for 24 hours under nor-
mal growth conditions. Treatments were then added to the cells
(2 final concentration) and incubated for an additional 24 hours.
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-
phenyl)-2H-tetrazolium, inner salt (MTS) solution (20 ml) was added
to media in each well 1–4 hours before the stipulated end point time.
Absorbance was measured at 490 nm using a Clariostar plate reader
(BMGLabtech Ltd., Aylesbury, U.K.) or a Flexstation 3 plate reader.
Patch Clamping. HEK-293 cells stably expressing hP2X4 were
plated onto 13-mm glass coverslips 24 hours before recording ATP-
induced membrane currents in the whole-cell patch clamp configura-
tion. An EPC10 amplifier (HEKA Elektronik, Harvard Bioscience
Inc., Lambrecht/Pfalz, Germany) was used to voltage clamp cells
at 260 mV. Borosilicate glass electrodes (World Precision Instru-
ments, Hitchin, U.K.) had a resistance of 5–8 MV when filled with
standard internal solution (145 mM NaCl, 10 mM HEPES, 10 mM
EGTA, pH 7.3, with 5 M NaOH). Cells were continually perfused by a
gravity feed with standard extracellular buffer solution (145 mM
NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 13 mM glucose, 10 mM
HEPES, pH 7.3) prior to seal formation. ATP and ginsenosides were
applied using a computer-controlled fast-flow system (Bio-Logic
Science Instruments, Seyssinet-Pariset, France) with the perfusion
capillaries placed in close proximity to the cell under investigation.
Cells were dialyzed with internal solution for 1 minute, and ATP in
the absence or presence of ginsenoside was applied every minute for
four applications.
Molecular Modeling and Docking. The coordinates of zebrafish
P2X4 in the ATP-bound open state (Hattori and Gouaux, 2012)
(Protein Data Bank: 4DW1) were used as a template. The sequence
of human P2X4 was aligned to the template using the ClustalW
algorithm (Larkin et al., 2007). The Schrödinger Prime software
(www.schrodinger.com) was used to construct an energy-based all-
atom model with the OPLS3 force field keeping the ATP coordinates
from the template. Three-dimensional models of the ginsenosides CK
and Rd were generated using LigPrep software within the Schrö-
dinger Maestro suite (www.schrodinger.com). The OPLS3 forcefield
was used to generate 32 low-energy conformers for each ginsenoside.
Induced fit docking was performed using the automated extended
sampling protocol in the Schrödinger Maestro suite (Sherman et al.,
2006). This first performs several initial docking runs in which side
chains are either trimmed, or their Van der Waals potentials softened
according to their flexibility. Side chains are then rebuilt, and those
within 5 Å of the ligand are optimized using Prime. Ligands were then
redocked to the new receptor structure using the Glide SP algorithm
(Friesner et al., 2004) and standard potentials. Structures within
30 kcal mol21 of the lowest energy structure were retained. The
receptor grid was centered on the highest-scoring potential binding
site, found using Sitemap (Halgren, 2007), and had cubic box
dimensions of 30 Å. Each of the 32 conformers was docked using the
extended sampling protocol. For each ginsenoside, the resulting poses
were clustered by heavy atom root-mean-square deviation (RMSD)
using the average-linkagemethod, and a representative structure was
chosen from the model closest to the centroid of the most populated
cluster. For CK and Rd, the most populated cluster made up 46% and
82% of all solutions, respectively.
Statistical Analysis. Graphswere plotted using GraphPad Prism
versions 6 or 7 (La Jolla, CA). Concentration–response curves were
fitted using a log (agonist) versus response–variable slope (four
parameter) best-fit equation. Data were analyzed for statistical signif-
icance using one-way analysis of variance (ANOVA) or two-wayANOVA
with post hoc tests as appropriate (GraphPad Prism). Significance was
taken as P , 0.05.
Results
For our investigation into the selectivity of protopanaxadiol
ginsenosides for P2X7, we chose the closely related P2X4
receptor because this is known to be coexpressed with P2X7 in
macrophages and other immune cells. We first generated a
HEK-293 cell line stably expressing a Glu-Glu C-terminal
Fig. 2. Ginsenosides enhance ATP responses at recombinant hP2X4. (A)
Various concentrations of ATP (100 nM to 100 mM) were used to activate
hP2X4, and YOPRO-1 uptake over 200 seconds was measured on a
Flexstation 3. Concentration response to ATP is shown in black, ATP in
the presence of 10 mM CK is shown in red, and ATP in the presence of
ivermectin (IVM; 5 mM) is shown in orange. Data are taken from three
independent experiments, and error bars represent S.E.M. Transformed
data were curve fit using nonlinear regression, and EC50 values were
1.92 mM ATP, 1.22 mM for ATP + CK, and 1.3 mM for ATP + IVM. (B)
Concentration response relationship for select ginsenosides on YOPRO-1
dye uptake to 5 mM ATP in HEK-hP2X4 cells. Ginsenosides were tested
over the range 0.1–50 mM. EC50 values were 7.5 mM Rd, 8.5 mM CK, and
10.5 mM Rb1. Data were taken from three independent experiments.
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tagged human P2X4 (HEK-hP2X4) and established an assay
to measure P2X4-mediated secondary pore responses via
YOPRO-1 dye uptake using a Flexstation 3 plate reader.
The ATP-induced YOPRO-1 dye uptake response could be
increased by ivermectin (3–5 mM) and reduced by the known
P2X4 antagonist 5-BDBD (20 mM) (Fig. 1). This confirms that
P2X4 receptors can elicit a large pore response in HEK-293
cells (Bernier et al., 2012). The standardized ginseng extract
G115 (100 mg/ml) was also found to increase the P2X4 dye
uptake response (Fig. 1B). We investigated the effect of the
individual purified ginsenoside chemicals on P2X4-mediated
YOPRO-1 dye uptake responses in HEK-293 cells. To do this,
we coinjected 10 mM of the following ginsenosides—CK, Rd,
Rb1, Rh2, or the aglycone PPD—together with ATP. Similar to
the reported potentiation of P2X7 (Helliwell et al., 2015), the
ginsenosides also potentiated P2X4 responses (Fig. 1, C and
D). The data suggest that Rd, CK, and Rb1 can potentiate
P2X4 (P , 0.05), whereas Rh2 and PPD had no effect on
ATP-induced P2X4 pore responses in HEK-293 cells.
We investigated whether ginsenoside CK could shift the
concentration–response curve to ATP and alter the sensitivity
of the P2X4 receptor to the agonist.We previously reported that
ginsenosideCKreduced theEC50 forATPatP2X7 inaddition to
increasing the maximum response elicited by ATP (Helliwell
et al., 2015). Using theYOPRO-1uptake assay, 10mMCKcould
increase themaximum response induced by ATP, similar to the
effect of the positivemodulator ivermectin (5mM) (Fig. 2A). The
EC50 value for ATP was 1.92 mM (95% confidence interval 1.03
to 3.56 mM) compared with 1.22 mM (confidence interval 0.49 to
2.99 mM) in the presence of CK, suggesting that CK does not
dramatically affect sensitivity to agonist. We also determined
the EC50 value for each ginsenoside on potentiation of hP2X4
responses (Fig. 2B), which were Rd 7.5 mM (confidence interval
5.74–9.91 mM), CK 8.5 mM (confidence interval 5.88–12.4 mM),
and Rb1 10.5 mM (confidence interval 8.46–13.23 mM).
Our next step was to investigate the effects of ginsenosides
on P2X4-mediated calcium responses using the HEK-hP2X4
stable cell line, as this is more physiologically relevant. Fura-2
acetoxymethyl ester–loaded HEK-hP2X4 cells were chal-
lenged with ATP (1 mM) in the absence or presence of 10 mM
CK, and calcium responses were measured for 300 seconds
(Fig. 3A). Endogenous P2Y receptors are known to contribute
to the ATP-induced calcium responses in HEK-293 cells;
however, a separate set of experiments confirmed that the
ginsenosides did not potentiate ADP- or UTP-mediated
calcium responses (Supplemental Fig. 1). Both CK and Rd
Fig. 3. Ginsenosides enhance Ca2+ influx responses in cells expressing hP2X4. Intracellular Ca2+ responses weremeasured in (A) Fura-2 acetoxymethyl
ester–loaded HEK-hP2X4 cells or (C) Fura-2 acetoxymethyl ester–loaded 1321N1-hP2X4 cells. Baseline values were recorded for 15–20 seconds,
and then ATP was automatically injected at 30 seconds (arrow indicates agonist addition). Representative ATP responses are shown in black; ATP
plus CK (10 mM) are shown in red. Error bars are S.D. (B) Ca2+ responses in HEK-hP2X4 were calculated as average Fura-2 ratio over the final
150 seconds. CK and Rd (10 mM) significantly increase hP2X4-mediated Ca2+ influx. *P, 0.05, one-way ANOVAwith Dunnett’s multiple comparison
post hoc test. (D) Ca2+ responses in 1321N1-hP2X4 cells weremeasured as area under the curve of zero baseline; error bars are S.D.; data are from four
independent experiments.
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caused an increase in the sustained calcium response
mediated by hP2X4 in HEK-293 cells (Fig. 3B) (P , 0.05).
We also generated a stable 1321N1 astrocytoma cell line
expressing hP2X4 and confirmed that the ginsenosides
CK and Rd potentiated ATP-induced calcium responses in
this second cell type (Fig. 3, C and D). Finally, to confirm
ginsenoside potentiation of hP2X4 channel responses, we
used whole-cell patch clamp recordings in HEK-hP2X4 cells.
As others have shown, multiple additions of ATP with a
washout period in between cause a rundown effect on
responses (Fig. 4A), in which the second response was 73%
6 5.8% of the initial response (n 5 7 cells). Figure 4B
demonstrates the effect of coadministering ATP in the pres-
ence of CK or Rd as the second application, showing that the
ginsenosides increase the ATP responses. Figure 4C sum-
marizes the patch clamp data as normalized data (percent-
age of second ATP application) (n 5 7–10 cells).
By measuring individual P2X receptors heterologously
expressed in HEK-293 and 1321N1 cells using a variety of
experimental techniques, we have demonstrated that se-
lected ginsenosides, namely CK and Rd, can potentiate
P2X4 responses. In our previous study, we investigated the
downstream consequences of potentiating P2X7 receptors
with the ginsenoside CK by determining its effect on ATP-
induced cell death in macrophages (Helliwell et al., 2015).
Therefore, we investigated whether P2X4 receptors play any
role in the induction of cell death and whether ginsenosides
could enhance this. We performed cell viability experiments
using cell viability MTS absorbance assays in HEK-293 cells
stably expressing either hP2X4 or hP2X7. In HEK-hP2X7
there was a reduction in cell viability with increasing concen-
trations of ATPwith concentrations greater than 1mM causing
cell death (Fig. 5). The selective P2X7 antagonist AZ10606120
(10 mM) could effectively block the cell death induced by these
high concentrations of ATP (Fig. 5). The presence of CK
enhanced the lethal effect of 500 mM ATP on P2X7 in these
experiments (Fig. 5). Conversely, in HEK-hP2X4 cells, there
was no meaningful reduction in cell viability with increasing
concentrations of ATP (Fig. 5); cells treated with 3 mM ATP
were fully viable (104% of control). Viabilitywas reduced to 86%
of control when 5-BDBD was introduced in combination with
high concentrations of ATP (1 and 3 mM) and viability was
reduced to 76% of control when CK was introduced with 3 mM
ATP (Fig. 5, P , 0.05).
To investigate the contribution of ginsenoside potentiation
of P2X4 responses versus ginsenoside potentiation of P2X7
responses in immune cells, we used the mouse microglia BV-2
cell line. These cells are known to express both P2X4 and P2X7
receptors (Gilbert et al., 2016; Asatryan et al., 2018). We
generated a P2X7-deficient BV-2 cell line using CRISPR/Cas9
gene-editing technology directed against exon 2 of mouse
P2X7. Single-cell clones of P2X7-deficient BV-2 cells were
generated and characterized using flow cytometry and West-
ern blotting to detect surface and total P2X7 protein, re-
spectively (Fig. 6, A and B). P2X4 protein expression was not
affected in BV-2 cells lacking P2X7 (Fig. 6B), and the
distribution of P2X4 appeared similar in BV-2 and P2X7-
deficient BV-2 cells (Fig. 6C). ATP (25 mM)-induced calcium
responses were similar in the BV-2 and P2X7-deficient BV-2
cells and displayed P2X4-like pharmacological properties such
as potentiation by ivermectin and reduction in responses
by two P2X4 antagonists 5-BDBD and PSB-12062 (Fig. 6D,
P , 0.05). In the parental BV-2 cells, both ginsenosides
CK and Rd gave a statistically significant potentiation of the
ATP-induced calcium response by 5.6-fold and 6.05 fold,
respectively (Fig. 7A, P, 0.05 by two-way ANOVA); however,
this effect was dramatically reduced in cells lacking P2X7
receptors to 1.6-fold (CK) and 1.1-fold (Rd) potentiation (Fig. 7,
A and B). This suggests that the majority of the ginsenoside
effect is due to their action on P2X7.We also demonstrate that
Fig. 4. Patch clamp analysis confirms CK, and Rd en-
hances ATP-induced currents. HEK-hP2X4 cells were volt-
age clamped at 260 mV, and (A) ATP (5 mM) was rapidly
applied for 5 seconds (pulse denoted by black bars), followed
by a 45-second washout with standard extracellular solu-
tion. In control cells, further applications of ATP were
applied every 1 minute for a total of four applications.
Human P2X4 responses were observed to display consistent
rundown. (B) In ginsenoside-treated cells, an initial control
application of ATP was administered and then the second
application was ATP plus CK or ATP plus Rd (both at
10 mM). (C) Normalized current amplitudes (pA/pF) show-
ing ATP rundown over the first four applications. Potenti-
ation of ATP responses by CK (red) and Rd (blue) expressed
as percentage of second ATP response.
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parental BV-2 cells were successfully killed by 3 mM ATP,
whereas P2X7-deficient BV-2 cells were protected from ATP-
induced cell death (Fig. 7C). The addition of CK (10 mM)
together with ATP did not induce or enhance any cell death in
P2X7-deficient BV-2 cells (Fig. 7C).
We have investigated putative binding sites on P2X4 and
P2X7 receptors for the ginsenosides using a homologymodel of
hP2X4 generated from the crystal structure of zfP2X4 in the
ATP-bound open state (Protein Data Bank: 4DW1). The
docking poses for both CK (Supplemental Material 1) and Rd
(Supplemental Material 2) on hP2X4 were similar to those
observed for hP2X7 (Fig. 8). There are notable differences in
the length of the internal loop at the top boundary of the
central vestibule, with this section being longer in hP2X4 and
containing two negatively charged glutamic acid residues
(-QEENS-) in comparison with neutral sequence -QGNS- in
hP2X7. This additional steric repulsion of the longer inter-
nal loop in P2X4, as well as electrostatic repulsion of the
diglutamate motif, may alter the binding mode of the ginseno-
sides comparedwith hP2X7. Figure 8, B andE, shows overlays
of the predicted docking poses for CK and Rd on hP2X7 and
hP2X4. Several interacting residues have been highlighted,
including E96 in the internal loop, S62 and D58 in the b-2
sheet, plus D320 in the b-14 sheet. Ginsenoside Rd binds in an
inverted orientationwith respect to CK, which is similar to the
docking pose observed on hP2X7 (unpublished data).
Discussion
In this study, we have described a novel positive allosteric
modulator for P2X4 and highlighted a putative binding site for
positive allosteric modulators that may be conserved between
P2X4 and P2X7 receptors. We have presented pharmacolog-
ical data for positive modulator activity at P2X4 and have
described important differences between ginsenoside action at
P2X4 and P2X7.
To measure P2X4 responses, we used a YOPRO-1 dye
uptake assay, which is most commonly used to measure
P2X7 responses. Earlier works suggested that dye uptake
responses could also be induced by other purinergic P2X
receptors, including P2X4 (Khakh et al., 1999a; Virginio
et al., 1999), and this was confirmed by Bernier et al. (2012)
in both transfected HEK-293 cells and microglia. This might
suggest that dye uptake is an intrinsic feature of P2X
receptor channels. Regardless of the mechanism underlying
permeation of large dye molecules, this is a potentially
useful way of measuring P2X4 responses in a medium- to
high-throughput system. We show that dye uptake was
induced by low concentrations of ATP, was potentiated by
ivermectin, and was reduced by pretreatment of the cells
with 5-BDBD, all characteristics of a P2X4-mediated re-
sponse. In these experiments, CK appeared to be more
effective at enhancing ATP-induced responses than iver-
mectin (Figs. 1 and 2).
Testing the protopanaxadiol ginsenosides on P2X4 in
YOPRO-1, calcium measurements and patch clamp recordings
revealed some differences to P2X7; the most striking difference
was that Rd was equivalent to CK in the level of potentiation it
induced on P2X4, whereas CK is more effective at P2X7.
Overall, the magnitude of potentiation observed for P2X4 was
much lower than on P2X7; ginsenosides typically increased
P2X4 responses by ∼twofold, whereas this reached .20-fold in
P2X7 responses by patch clamp analysis (Helliwell et al., 2015).
The similar PAM action on P2X4 and P2X7 prompted an
investigation into whether the predicted binding site for
ginsenosides would be the same. There is a high degree of
similarity between these channels, and we used the zfP2X4
crystal structure to predict the ATP-bound open states of
hP2X4 and hP2X7. Differences in the binding poses were
observed and in amino acid residues predicted to interact with
bound ginsenosides, the roles of which will be investigated in a
more detailed study. It is notable that the predicted ginsenoside
site does not overlap with the ivermectin binding site on P2X4,
which is thought to be located within the transmembrane
domains (Jelínková et al., 2006; Silberberg et al., 2007; Popova
et al., 2013), suggesting that two distinct positive modulator
binding sites exist for P2X4.
In this study, we have paid particular attention to the
cytotoxic action of ATP. It is well known that sustained
activation of P2X7 leads to cell death (Orioli et al., 2017),
and we have shown that ginsenosides can enhance this
(Helliwell et al., 2015). The role of other purinergic receptors
in cell death is not so clear, and therefore we investigated the
involvement of P2X4 in this process. We found that sustained
activation of hP2X4 overexpressed in HEK-293 cells did not
cause cell death (Fig. 5), and furthermore, high concentrations
of ATP were not cytotoxic in P2X7-deficicent BV-2 microglial
Fig. 5. Ginsenoside CK does not enhance cell death in HEK-hP2X4 cells.
HEK-293 cells stably expressing hP2X4 or hP2X7 (50,000 cells/well) were
plated into 96-well plates for 24 hours prior to stimulation with ATP.
Cells were pretreated with antagonists AZ10606120 (AZ) or 5-BDBD for
10 minutes before ATP was added. Cells were exposed to the indicated
concentrations of ATP or ATP + CK (10 mM) for 24 hours, and viability was
measured using MTS absorbance. MTS was added for the final 4 hours of
incubation, and absorbance read using a Flexstation 3 reader. Data were
normalized to cells treated with vehicle control and are expressed as
percentage of control. Data are from four independent experiments.
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Fig. 6. P2X4 responses in gene-edited BV-2 cells to eliminate P2X7 receptors. BV-2 cells deficient for P2X7 were generated using CRISPR/Cas9 editing.
(A) Flow cytometry data indicating parental BV-2 cells express P2X7 (black histogram), whereas P2X7-deficient BV-2 cells show no P2X7-positive stain
(green histogram) using Hano43 antibody labeling. Red histogram indicates negative control, cells labeled with secondary antibody only. (B) Western
blots showing no anti-P2X7 reactive protein band in P2X7-deficient BV-2 cells compared with parental BV-2 and J774 macrophages. Equal amounts of
protein (25 mg) were loaded per lane as indicated by the b-actin loading control on stripped and reprobed blots. P2X4 protein levels were unchanged
following knockout of P2X7. (C) Staining for P2X4 receptors was performed using a fix/perm method with cells grown on 13-mm glass coverslips. Rabbit
anti-P2X4 (1:200) was used to label all P2X4 receptors in BV-2 parental and P2X7-deficient BV-2 cells. Images are representative of two independent
experiments. (D) Intracellular calciummeasurements in Fura-2 acetoxymethyl ester–loaded BV-2 and P2X7-deficient BV-2 show identical ATP (25 mM)
responses. ATP + ivermectin (3 mM) responses were reduced by pretreatment of cells with 5-BDBD (10 mM) or PSB-12062 (1 mM). Error bars are S.D. and
*P , 0.05, one-way ANOVA with Dunnett’s multiple comparison post hoc test.
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cells (Fig. 7), suggesting that activation of P2X4 does not cause
cell death. In HEK-hP2X7 cells, CK was able to enhance cell
death to nonlethal concentrations of ATP (500mM), similar to
J774 cells (Helliwell et al., 2015). This is likely due to the
increased receptor sensitivity to ATP in the presence of CK,
allowing cells to overcome a threshold level of signaling for
the initiation of apoptosis. CK was not as effective at
enhancing cell death in response to 1 or 3 mM ATP; however,
this may be due to maximum cell death being induced by full
activation of P2X7.
Positive allosteric modulators for P2X4 are thought to be
useful in treatment of alcohol-use disorders due to a compet-
itive effect on channel activity (Asatryan et al., 2010; Yardley
et al., 2012). Ethanol has an inhibitory effect on P2X4
responses and prevents the action of ATP, which in turn
affects the modulation of neurotransmission in various re-
gions of the brain (Franklin et al., 2014). The binding of
ivermectin to P2X4 is postulated to counteract the binding of
ethanol, thus preventing its inhibitory effect on channel
activation. It would be interesting to determine whether
positive allosteric modulators that bind to other regions of
the channel will have a similar effect on elimination of ethanol
effects on P2X4. In addition to alcohol-use disorders, P2X4 has
been implicated in the regulation of dopamine-dependent
behaviors (Khoja et al., 2016), suggesting that modulation
of P2X4 in the CNS may also be beneficial in dopaminer-
gic disorders such as Parkinson’s disease. Interestingly,
P. ginseng extract is reported to have some beneficial effects
in animal models of Parkinson’s disease (Van Kampen et al.,
2014). However, due to their chemical properties, it is
unclear how easily the ginsenosides cross the intact blood-
brain barrier. A recent study suggests ginsenosides can be
detected in rat vascular endothelial cells and astrocytes
following oral administration of high purity ginseng total
saponins (Zhao et al., 2018). The larger ginsenosides with
multiple sugar moieties are much less likely to be absorbed
from the intestine into the bloodstream, but the smaller
ginsenosides and metabolites such as CK are found at
appreciable concentrations in plasma and liver. Peak plasma
concentrations of CK are reported to be 8.35 ng/ml (low nM
range) in humans following oral administration of Korean
red ginseng extract (Kim, 2013), although a more recent
study foundhigher plasma concentrations (1183.26445.1 ng/ml
following a single 800 mg dose) in volunteers receiving pure
Ginsenoside CK tablets (Chen et al., 2018). Furthermore, the
source of the ginsenosides, whether from a natural extract,
Fig. 7. Ginsenosides show little potentiation of ATP-induced responses in BV-2 microglia in the absence of P2X7. (A and B) Intracellular calcium
measurements were performed using a no-wash Fura-2-QBT assay on parental BV-2 cells and P2X7-deficient BV-2 microglia cells. ATP (200 mM) was
injected in the absence or presence of various ginsenosides (all 10 mM). Calcium responses were calculated as area under curve using Softmax Pro
software. Significant potentiation was only evident in cells expressing P2X7. Data are from three independent experiments, error bars represent S.D.,
and *indicates P , 0.05 using two-way ANOVA with Bonferroni’s multiple comparison post hoc test. (C) Cell viability was assessed using MTS
reagent. BV-2 cells were plated for 24 hours prior to stimulation with ATP in the absence or presence of ginsenoside CK (10mM). Cells were treated for
24 hours, and MTS was added for the final 1 hour. Data are represented as mean percentage of control values in which control was vehicle-treated
cells. Data are from three independent experiments, error bars represent S.D., and *indicates P , 0.05 using one-way ANOVA with Dunnett’s
multiple comparison post hoc test.
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supplement, high purity chemicals, total saponins, plus the
route of administration, length of dosing, and the influence
of the gut microbiota are all factors that are likely to affect
plasma levels. It also remains unclear whether reported
CNS effects are due to peripheral effects. As these natural
products gain recognition for their potential therapeutic
benefits, more detailed studies are likely to be conducted in
humans.
There are several processes in which P2X4 has been shown
to play a role; in endothelial cells P2X4 is reported to be
involved in a vasodilatory effect induced by shear stress
(Yamamoto et al., 2000), and in the hippocampus P2X4 has a
role in long-term potentiation (Sim et al., 2006). Enhance-
ment of these physiologic processes may be beneficial in
people suffering from hypertensive disorders or cognitive/
memory deficit, and positive allosteric modulators may be a
useful future strategy for manipulating P2X4 receptors. It
has also been shown that activation of P2X4 can cause
surfactant secretion in the lung (Miklavc et al., 2013),
chemokine and prostaglandin E2 secretion from macro-
phages (Ulmann et al., 2010; Layhadi et al., 2018), and
BDNF secretion from spinal microglia (Coull et al., 2005;
Ulmann et al., 2008). It is less clear whether enhancement of
such responses would be beneficial, particularly in the case of
the P2X4-BDNF axis in neuropathic pain. However, we have
shown that the action of CK and Rd ginsenosides on P2X4-
mediated calcium responses in microglial cells is minor (Fig.
7), and this may be due to the low surface expression of P2X4
in these cells (Qureshi et al., 2007; Stokes and Surprenant,
2009). Alternatively, the ginsenosides may be less active on
mouse P2X4 receptors relative to human P2X4 receptors,
because the BV-2 cell line is of mouse origin. It is unlikely
that ginsenosides would enhance neuropathic pain because
concentrations in the CNS would be much lower than plasma
concentrations and below the levels reported in this study to
potentiate P2X4. Peripheral P2X4 receptors are therefore
Fig. 8. Molecular model of hP2X4 with CK and Rd docked into a predicted central vestibule binding site. (A) Representation of a homology model of
trimeric hP2X4 in the open (ATP-bound) state with ginsenoside CK docked in the central vestibular region. Each subunit chain is differentially colored
(green, cyan, and magenta). (B) A zoomed-in view of the binding site to compare CK pose docked to hP2X4 (yellow) to CK pose docked to hP2X7 (purple).
(C) A rotated view of the CK binding site from the inside of the cavity facing outward (rotation of 180°). Polar contacts are highlighted between CK and
b-sheets lining the lower body region. (D) Trimeric hP2X4model with ginsenoside Rd docked into the central vestibule binding site. (E) A zoomed-in view
of the binding site to compare Rd pose docked to hP2X4 (yellow) to Rd pose docked to hP2X7 (purple). (F) Same rotated view of the Rd binding site from the
inside of the cavity facing outwards (rotation of 180°). Polar contacts are highlighted between Rd and b-sheets lining the lower body region and E96 in the
internal loop region. Ligands and side chains are represented as sticks with all hydrogen atoms omitted for clarity. Images were generated in Pymol.
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more likely to be modulated by circulating ginsenosides or
ginsenosides accumulated in tissues such as liver and lung.
In conclusion, we have demonstrated that ginsenosides are
not selective in their potentiating action on P2X7 receptors,
but have some PAM activity on P2X4 receptors most likely
through a similar binding site in the large ectodomain of these
trimeric channel complexes.
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Supplementary Figure 1: Ginsenosides have no effect on P2Y-induced Ca2+ 
responses in HEK-293 cells.  
Intracellular Ca2+ responses were measured in fura-2AM loaded HEK-293 cells using 
a Flexstation 3 plate reader. Baseline values were recorded for 20 seconds and then 
nucleotide agonists (ATP, ADP, and UTP) were automatically injected. A 
representative UTP-induced response is shown in black, UTP plus CK (10 μM) is 
shown in red. Error bars are SEM. Bar charts show quantification of peak Ca2+ 
responses in HEK-293 cells in response to agonist (ATP, ADP or UTP) + 
ginsenoside CK, Rd, Rb1, Rh2 or aglycone PPD (10 µM). ns represents P > 0.05, 
one-way ANOVA with Dunnett’s multiple comparison post-hoc test. 
 
Data Supplement 1: hP2X4 homology model with CK docked  
 
Data Supplement 2: hP2X4 homology model with Rd docked  
 
 
